ライフサイエンスコーパス: oophorectomy

1 , and previous hysterectomy (with or without oophorectomy).

2 in the same population who had not undergone oophorectomy.

3 he efficacy of prophylactic hysterectomy and oophorectomy.

4 are these with women who had not received an oophorectomy.

5 rospectively for breast cancer incidence and oophorectomy.

6 not undergone hysterectomy, with or without oophorectomy.

7 dy participants were censored at the time of oophorectomy.

8 from 3.34 to 4.65 years, depending on age at oophorectomy.

9 iestrogen therapy, i.e., progesterone and/or oophorectomy.

10 , irrespective of whether HRT was used after oophorectomy.

11 undergoing both prophylactic mastectomy and oophorectomy.

12 e of hormone replacement therapy (HRT) after oophorectomy.

13 8 and 8.6 years after bilateral prophylactic oophorectomy.

14 for ovarian cancer or risk-reducing salpingo-oophorectomy.

15 horectomy and 55 with a concurrent bilateral oophorectomy.

16 as adjusted for age, smoking, and unilateral oophorectomy.

17 bilateral mastectomies and 68%, prophylactic oophorectomy.

18 bdominal hysterectomy and bilateral salpingo-oophorectomy.

19 develop in a woman years after prophylactic oophorectomy.

20 ephrectomy; 134985, hysterectomy; and 27445, oophorectomy.

21 th total hysterectomy and bilateral salpingo-oophorectomy.

22 g surgery in the form of unilateral salpingo-oophorectomy.

23 procedures, ie, bilateral mastectomy and/or oophorectomy.

24 ecular bone sustained by rats within 6 wk of oophorectomy.

25 t of premenopausal women underwent bilateral oophorectomy.

26 ed for women who did and who did not undergo oophorectomy.

27 e that developed in women after menopause or oophorectomy.

28 106 women had a hysterectomy with bilateral oophorectomy.

29 ucocele 2 years after risk-reducing salpingo-oophorectomy.

30 1 mutation, survival was much improved after oophorectomy.

31 undergone a hysterectomy with or without an oophorectomy.

32 prior hormone-sensitive cancers or bilateral oophorectomy.

33 at menopause, or history of hysterectomy or oophorectomy.

34 047 (10.4%) hysterectomies, and 1782 (6.5%) oophorectomies.

35 to have mastectomies and 33% (4/12) to have oophorectomies.

36 (95% CI, 1.34-1.50) after oophorectomy vs no oophorectomy, 0.88 (95% CI, 0.85-0.90) after hysterectom

37 compared with not having had a hysterectomy/oophorectomy (1.51; 1.34-1.71).

38 1293 women with unilateral oophorectomy, 1097 with bilateral oophorectomy, and 2390

39 Six women who underwent prophylactic oophorectomy (2.3 percent) received a diagnosis of stage

40 Among premenopausal women who had unilateral oophorectomy, 21 percent were on HRT at 3 months, increa

41 6 years with both tamoxifen and prophylactic oophorectomy, 3.5 years with prophylactic mastectomy, an

42 en seen at our clinic underwent prophylactic oophorectomy, 33 of whom had a calculated risk of carryi

43 with tamoxifen, 2.6 years with prophylactic oophorectomy, 4.6 years with both tamoxifen and prophyla

44 ad undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutation-posit

45 with tamoxifen, 4.4 years with prophylactic oophorectomy, 6.3 years with tamoxifen and oophorectomy,

46 with BRCA1/2 mutations undergo prophylactic oophorectomy after completion of childbearing, decide ab

47 Of the 676 women, 345 underwent oophorectomy after the diagnosis of breast cancer and 33

48 s, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, resp

49 an incremental cost-effectiveness ratio over oophorectomy alone of 2352 dollars per life-year for BRC

50 The increased rate of oophorectomy among mutation carriers suggests that testi

51 The QALYs saved were 0.5 for oophorectomy and 1.9 for the combined procedures in the

52 omy: 42 without oophorectomy or a unilateral oophorectomy and 55 with a concurrent bilateral oophorec

53 ately 4 years with hysterectomy and salpingo-oophorectomy and adherence to colorectal cancer screenin

54 ptibility genes BRCA1 or BRCA2, prophylactic oophorectomy and bilateral mastectomy have emerged as pr

55 h prior or concurrent bilateral prophylactic oophorectomy and by approximately 90% in women with inta

56 and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy,

57 on at baseline between years since bilateral oophorectomy and common carotid artery intima-media thic

58 on-based sample of women who had received an oophorectomy and compare these with women who had not re

59 plained by greater frequency of hysterectomy/oophorectomy and earlier age at surgery after endometrio

60 women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine

61 history of premenopausal surgery, bilateral oophorectomy and hysterectomy without oophorectomy were

62 In women who have undergone oophorectomy and hysterectomy, transdermal testosterone

63 men who had undergone bilateral prophylactic oophorectomy and in 142 matched controls.

64 men who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not und

65 lity adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively.

66 idates for risk reduction strategies such as oophorectomy and mastectomy.

67 ures (including a laparotomy and at least an oophorectomy and omental biopsy) in each group of the st

68 2 testing on the utilization of prophylactic oophorectomy and ovarian cancer screening.

69 gen replacement therapy (ERT), or history of oophorectomy and pancreatic cancer.

70 he 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cancer was diagnosed in 1 wo

71 tisite randomized clinical trial of adjuvant oophorectomy and tamoxifen for 5 years or observation an

72 in a randomized controlled trial of adjuvant oophorectomy and tamoxifen or observation who had estrog

73 may favorably influence response to adjuvant oophorectomy and tamoxifen treatment in patients with es

74 re significantly improved following adjuvant oophorectomy and tamoxifen.

75 enefit from adjuvant treatment with surgical oophorectomy and tamoxifen.

76 9 women who underwent bilateral prophylactic oophorectomy and who were studied to determine the risk

77 c oophorectomy, 6.3 years with tamoxifen and oophorectomy, and 2.6 years with mastectomy, or with bot

78 unilateral oophorectomy, 1097 with bilateral oophorectomy, and 2390 referent women were eligible for

79 (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to

80 bdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles of intrav

81 cologic procedures including tubal ligation, oophorectomy, and partial hysterectomy have been demonst

82 es (cholecystectomy, colectomy, hysterectomy/oophorectomy, and prostatectomy) between 1987 and 2004.

83 bout effects of HRT, effects of prophylactic oophorectomy, and risks of cancer associated with BRCA1/

84 and/or amenorrhea lasting >6 months, and/or oophorectomy, and/or increased follicle-stimulating horm

85 ," "preventive," "bilateral," "mastectomy," "oophorectomy," and "ovariectomy," a MEDLINE search of th

86 Cohort studies suggest that women with oophorectomy are at greater risk for CHD than intact wom

87 hat women who undergo prophylactic bilateral oophorectomy are at increased risk of death for all caus

88 ancer risk reductions conferred by bilateral oophorectomy are not strongly confounded by failure to a

89 Prophylactic mastectomy and oophorectomy are often considered as ways of reducing th

90 Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRC

91 ctomy, partial nephrectomy, hysterectomy, or oophorectomy at 1370 hospitals in the United States from

92 ldbearing, decide about short-term HRT after oophorectomy based largely on quality-of-life issues rat

93 cted on women who had undergone prophylactic oophorectomies because of the elevated risk of ovarian c

94 omen who had received prophylactic bilateral oophorectomy before the age of 45 years than in referent

95 Therefore, women who underwent bilateral oophorectomy before the onset of menopause or women who

96 f-reported receipt of bilateral prophylactic oophorectomy (BPO) and utilization of CA-125 and transva

97 Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduct

98 onsider the option of bilateral prophylactic oophorectomy (BPO), in the hope that removal of healthy

99 Bilateral prophylactic salpingo-oophorectomy (BPSO) is used widely used to reduce the ri

100 ons between hysterectomy, bilateral salpingo-oophorectomy (BSO), and incidence of diabetes in postmen

101 omy, by 2.8 to 3.4 years; and mastectomy and oophorectomy, by 3.3 to 6.0 years over surveillance.

102 n women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the im

103 age or older who had not undergone bilateral oophorectomy chose to undergo either surveillance for ov

104 t increased in women who underwent bilateral oophorectomy compared with referent women.

105 breast cancer risk associated with bilateral oophorectomy could be affected by common conditions that

106 was ignored, the strong protective effect of oophorectomy, coupled with the high prevalence of the pr

107 omen without surgery; risk-reducing salpingo-oophorectomy decreased breast cancer incidence by 37% to

108 Oophorectomy decreased the splenic homing, autoantibody

109 at premenopausal hysterectomy with bilateral oophorectomy decreases the risk of breast cancer in blac

110 7 years of life expectancy from prophylactic oophorectomy, depending on their cumulative risk of canc

111 In contrast, although oophorectomy did not significantly influence rAAV transd

112 With quality adjustment, oophorectomy dominated all other strategies for BRCA1 an

113 the 33 mutation-positive women who underwent oophorectomy during follow-up developed breast cancer, c

114 Prophylactic mastectomy and prophylactic oophorectomy, effective in retrospective clinical experi

115 rst birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height.

116 50-87, we analysed those who had received an oophorectomy for a non-cancer indication before the onse

117 ce surgical menopause following hysterectomy/oophorectomy for noncancerous conditions; it is also com

118 rning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer

119 dentified through risk-reducing prophylactic oophorectomy from three women with germline BRCA1 mutati

120 ause, and cancer treatments such as surgical oophorectomy, gonadotropin-releasing hormone agonists, c

121 years since hysterectomy in the no bilateral oophorectomy group (beta = 0.005 (standard error, 0.023)

122 ynecologic cancer was longer in the salpingo-oophorectomy group, with a hazard ratio for subsequent b

123 terectomy by about a fourth in the bilateral oophorectomy group.

124 o-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, includi

125 eries (prophylactic bilateral mastectomy and oophorectomy) had an incremental cost-effectiveness rati

126 nd ovarian cancer, but it is unclear whether oophorectomy has an impact on survival in women with BRC

127 Prophylactic salpingo-oophorectomy has been demonstrated to decrease the risk

128 ered after randomisation to have a bilateral oophorectomy, have ovarian cancer, or had exited the reg

129 served (HOC), or hysterectomy with bilateral oophorectomy (HBSO).

130 nal hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm delivery, and stillbirth for

131 ween women who underwent hysterectomy and/or oophorectomy (higher odds for less educated women) and t

132 last births, age at menopause, hysterectomy, oophorectomy, hormone therapy use, and body mass index (

133 liparity (HR 2.14, P = 0.01), and unilateral oophorectomy (HR 6.51, P < 0.0001).

134 s of age (HR 2.36, P = 0.01), and unilateral oophorectomy (HR 9.76, P < 0.0001) were independent dete

135 ure, including age at bilateral prophylactic oophorectomy if applicable.

136 hylactic hysterectomy; and 52%, prophylactic oophorectomy if they tested positive for a mutation.

137 according to her cancer risks, prophylactic oophorectomy improved survival by 0.4 to 2.6 years; mast

138 Among women who had undergone bilateral oophorectomy, IMT was significantly related to years sin

139 Salpingo-oophorectomy in carriers of BRCA mutations can decrease

140 s recorded in women who underwent unilateral oophorectomy in either overall or stratified analyses.

141 the efficacy of prophylactic mastectomy and oophorectomy in preventing breast and ovarian cancer to

142 oncology but may be useful for prophylactic oophorectomy in selected individuals.

143 The benefits of oophorectomy in this setting are unknown, and the proced

144 nancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations.

145 hylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome.

146 ylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preventing end

147 Oophorectomy is associated with a decrease in mortality

148 Oophorectomy is commonly performed in premenopausal wome

149 Preventive salpingo-oophorectomy is currently the only method known to reduc

150 The decision about prophylactic oophorectomy is difficult for many premenopausal women w

151 RCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the appendix.

152 Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA mut

153 Bilateral oophorectomy is often performed during hysterectomy for

154 Preventive bilateral salpingo-oophorectomy is recommended to women with a BRCA mutatio

155 In our model, prophylactic oophorectomy lengthened life expectancy in women with BR

156 Differing rates of oophorectomy likely represent an underappreciated basis

157 After bilateral oophorectomy, many women report impaired sexual function

158 fen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or surveillanc

159 Among 30-year-old women, oophorectomy may be delayed 10 years with little loss of

160 age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that careful sta

161 ysterectomy status with or without bilateral oophorectomy might increase risk for CVD, but most studi

162 al gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRC

163 h lower odds of breast cancer (for bilateral oophorectomy, multivariable-adjusted odds ratios = 0.60,

164 terval: 0.47, 0.77; for hysterectomy without oophorectomy, multivariable-adjusted odds ratios = 0.68,

165 primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches

166 f removing endogenous estrogen, we performed oophorectomies on Pten(+/-) mice.

167 tomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-y

168 apy reverses the adverse effect of bilateral oophorectomy on coronary heart disease.

169 viduals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one e

170 en women reported a hysterectomy: 42 without oophorectomy or a unilateral oophorectomy and 55 with a

171 in the smaller group of women with bilateral oophorectomy or hysterectomy with one ovary retained.

172 sociated with breast cancer risk, but either oophorectomy or hysterectomy, or both, and the timing of

173 Exclusion criteria were previous bilateral oophorectomy or ovarian malignancy, increased risk of fa

174 o patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as t

175 sing hormone analogue triptorelin, bilateral oophorectomy, or bilateral ovarian irradiation were used

176 ropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation.

177 gnant tumor are not uncommon in prophylactic oophorectomies performed in women at very high risk for

178 r of women experience early menopause due to oophorectomy performed for benign indications.

179 my (PM) at various ages, and/or prophylactic oophorectomy (PO) at ages 40 or 50 years in 25-year-old

180 hylactic mastectomy (PM) and/or prophylactic oophorectomy (PO) at various ages.

181 hypothesized that population differences in oophorectomy prevalence might significantly influence br

182 ncy or cancer prevention through castration (oophorectomy), preventing chemically induced mouse carci

183 Oophorectomy reduced renal medullary eNOS levels to that

184 Oophorectomy reduced renal medullary iNOS levels to that

185 Because prophylactic oophorectomy reduces breast cancer risk by approximately

186 Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial can

187 bdominal hysterectomy and bilateral salpingo-oophorectomy revealed similar estimates (HR, 0.59; 95% C

188 Risk-reducing bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy are wi

189 Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as a key com

190 Risk-reducing salpingo-oophorectomy (RRSO) is effective in decreasing risks of

191 Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women wi

192 Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal

193 Risk-reducing salpingo-oophorectomy (RRSO) was encouraged throughout the study.

194 s risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified Jewish s

195 duction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become an important component o

196 ngly choose bilateral risk-reducing salpingo-oophorectomy (RRSO).

197 t cancer and a BRCA1 mutation should undergo oophorectomy shortly after diagnosis.

198 ancer was diagnosed at surgery, prophylactic oophorectomy significantly reduced the risk of coelomic

199 lated tumor predisposition, and explains why oophorectomy significantly reduces breast cancer risk an

200 s of these mutations, risk-reducing salpingo-oophorectomy significantly reduces morbidity and mortali

201 rian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this

202 een determined; however, estrogen reduction (oophorectomy) significantly reduces recurrence in premen

203 st birth, age at menarche, age at menopause, oophorectomy, smoking, and education.

204 assess the association between hysterectomy/oophorectomy status and diabetes incidence.

205 No study has taken oophorectomy status into account in estimating penetranc

206 Women with a hysterectomy (regardless of oophorectomy status) had an adverse risk profile at base

207 Hysterectomy (regardless of oophorectomy status) was a significant predictor of CVD

208 we observed that hysterectomy, regardless of oophorectomy status, was associated with increased risk

209 ty in women and may vary by hysterectomy (or oophorectomy) status.

210 nalysis of ovarian tissues from prophylactic oophorectomies, suggest that depletion of ovarian follic

211 gainst prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutatio

212 BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oop

213 n who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was assoc

214 Although prophylactic bilateral oophorectomy undertaken before age 45 years is associate

215 with breast conservation surgery who undergo oophorectomy versus sporadic controls.

216 y stroke were 1.42 (95% CI, 1.34-1.50) after oophorectomy vs no oophorectomy, 0.88 (95% CI, 0.85-0.90

217 peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P < .001).

218 mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P < .001).

219 uted to breast cancer in women who underwent oophorectomy was 0.38 (95% CI, 0.19-0.77; P = .007) for

220 isk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian

221 Preventive oophorectomy was associated with an 80% reduction in the

222 Hysterectomy/oophorectomy was associated with higher risk of CHD and

223 Having had a hysterectomy/oophorectomy was associated with higher risk of combined

224 Oophorectomy was associated with improved survival in BR

225 use, the finding that years since bilateral oophorectomy was associated with increasing atherosclero

226 g salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortali

227 Use of HRT after oophorectomy was associated with relatively small change

228 Hysterectomy with oophorectomy was associated with significantly lower tes

229 idence of IBTR in carriers who had undergone oophorectomy was not significantly different from that i

230 k demonstrated that the protective effect of oophorectomy was strongest among women who were premenop

231 ter severity of lung disease, menopause, and oophorectomy were associated with greater decline in BMD

232 ateral oophorectomy and hysterectomy without oophorectomy were associated with lower odds of breast c

233 ence and all-cause mortality associated with oophorectomy were evaluated using time-dependent surviva

234 ho did not have previous cancer or bilateral oophorectomy were followed-up for an average of 5.3 year

235 re postmenopausal or who underwent bilateral oophorectomy were less likely to have hot flashes if the

236 ctor of IBTR when carriers who had undergone oophorectomy were removed from analysis (HR, 1.99; P = .

237 women who underwent unilateral or bilateral oophorectomy while residing in Olmsted County, MN, USA,

238 sociations of premenopausal hysterectomy and oophorectomy with breast cancer risk.

239 ship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes.

240 A 36-year-old woman underwent a right oophorectomy with cryopreservation of ovarian cortical s

241 Women who underwent bilateral oophorectomy with hysterectomy at age </= 40 years had s

242 red prophylactic mastectomy and prophylactic oophorectomy with no prophylactic surgery among women wh

243 comparison of women who underwent bilateral oophorectomy with referent women provided evidence for a

244 ompared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cance

245 after hysterectomy with or without bilateral oophorectomy with the changes observed up to and after n

246 -Meier curves to compare women who underwent oophorectomy with those who had ovarian preservation.

247 n who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy

248 %, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, an